{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-037650","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.026728+00:00","generated_at":"2026-05-26T02:25:25.160645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Disc Medicine: 2024 net loss $109.4M, bitopertin NDA on track H2 2025 via accelerated approval","bullets":["Full-year 2024 net loss $109.4M vs $76.4M in 2023; R&D expenses rose to $96.7M.","Cash $489.9M at year-end; plus $243.3M net from Jan 2025 offering, funds operations into 2028.","Bitopertin: FDA path to accelerated approval for EPP; NDA submission planned H2 2025.","DISC-0974: Phase 2 MF anemia trial initiated; initial data expected H2 2025.","DISC-3405: Phase 2 in polycythemia vera expected H1 2025; Phase 1 showed proof-of-mechanism."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-037650","json":"https://secwatch.observer/filing/0001193125-25-037650.json","markdown":"https://secwatch.observer/filing/0001193125-25-037650.md","text":"https://secwatch.observer/filing/0001193125-25-037650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/0001193125-25-037650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/d916827d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:25:25.160645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}